Establishment Labs Sees EBITDA Profitability by Early 2026 After 102% Share Surge
Carillon Eagle Small Cap Growth Fund cited Establishment Labs Holdings as a leading Q4 2025 contributor after its Motiva breast implant line outpaced industry growth. Following FDA approval in late 2024, the company forecasts EBITDA profitability by early 2026 and projects cash flow positivity within the same year.
1. Fund Highlights Establishment Labs
The Carillon Eagle Small Cap Growth Fund identified Establishment Labs as one of its top contributors in fourth quarter 2025, attributing strong performance to the Motiva breast implant line and robust sector demand. This recognition underscores the company's growing influence in small-cap growth portfolios.
2. FDA Approval Spurs Demand and Profitability Outlook
Following FDA approval of the Motiva line in late 2024, Establishment Labs recorded accelerated revenue growth in 2025, significantly outpacing industry peers. Management expects EBITDA profitability by early 2026 and cash flow positivity later in the same year.
3. Share Performance and Market Capitalization
Establishment Labs shares closed at $74.60 on February 13, 2026, delivering an 8.35% return over the past month and a 102.73% gain over the past twelve months. The company holds a $2.125 billion market capitalization, reflecting strong investor confidence.
4. Product Pipeline and FDA Applications
Establishment Labs has filed for FDA clearance of a new implant for primary and revision breast reconstruction, signaling an expansion of its product portfolio and potential for further revenue growth.